Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8
Adoptive Transfer
Animals
CD8-Positive T-Lymphocytes
/ immunology
Cell Line, Tumor
Cell Membrane Permeability
Cell Proliferation
Cell Survival
Female
Lymph Nodes
/ immunology
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ immunology
Magnetite Nanoparticles
/ chemistry
Mice, Inbred C57BL
Neoplasm Transplantation
Neoplasms, Experimental
/ immunology
Propylamines
/ chemistry
Silanes
/ chemistry
Cancer immunotherapy
Cell-based therapy
Effector T cell
Magnetic nanoparticle
Magnetic retention
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
06 Aug 2019
06 Aug 2019
Historique:
received:
11
06
2019
accepted:
30
07
2019
entrez:
8
8
2019
pubmed:
8
8
2019
medline:
15
8
2019
Statut:
epublish
Résumé
Adoptive T cell-transfer (ATC) therapy is a highly promising cancer-treatment approach. However, in vivo-administered T cells tend to disperse, with only a small proportion reaching the tumour. To remedy this, magnetic targeting of T cells has been recently explored. Magnetic nanoparticles (MNPs) functionalised with antibodies were attached to effector T cells and magnetically recruited to tumour sites under MRI guidance. In this study, we investigated whether 3-aminopropyl-triethoxysilane (APS)-coated MNPs directly attached to CD8 First, we show that antigen-specific CD8 The use of an EMF to improve targeting of tumour-specific T cells modified with APS-MNPs reduced the percentage of these cells infiltrating the tumour, but promoted the retention and the persistence of these cells in the tumour-draining LNs.
Sections du résumé
BACKGROUND
BACKGROUND
Adoptive T cell-transfer (ATC) therapy is a highly promising cancer-treatment approach. However, in vivo-administered T cells tend to disperse, with only a small proportion reaching the tumour. To remedy this, magnetic targeting of T cells has been recently explored. Magnetic nanoparticles (MNPs) functionalised with antibodies were attached to effector T cells and magnetically recruited to tumour sites under MRI guidance. In this study, we investigated whether 3-aminopropyl-triethoxysilane (APS)-coated MNPs directly attached to CD8
RESULTS
RESULTS
First, we show that antigen-specific CD8
CONCLUSIONS
CONCLUSIONS
The use of an EMF to improve targeting of tumour-specific T cells modified with APS-MNPs reduced the percentage of these cells infiltrating the tumour, but promoted the retention and the persistence of these cells in the tumour-draining LNs.
Identifiants
pubmed: 31387604
doi: 10.1186/s12951-019-0520-0
pii: 10.1186/s12951-019-0520-0
pmc: PMC6683429
doi:
Substances chimiques
Magnetite Nanoparticles
0
Propylamines
0
Silanes
0
amino-propyl-triethoxysilane
L8S6UBW552
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : Spanish Ministry of Economy, Industry and Competitiveness
ID : SAF-2014-54057-R
Organisme : Spanish Ministry of Economy, Industry and Competitiveness
ID : SAF-2017-82223-R
Organisme : Spanish Ministry of Economy, Industry and Competitiveness
ID : FPU13/05037
Organisme : Spanish Ministry of Economy, Industry and Competitiveness
ID : FPU15/06170
Références
J Immunol. 1999 Mar 1;162(5):2858-66
pubmed: 10072534
Immunol Cell Biol. 2000 Apr;78(2):110-7
pubmed: 10762410
J Immunol Methods. 2001 Oct 1;256(1-2):89-105
pubmed: 11516758
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
J Exp Med. 2002 Feb 4;195(3):317-26
pubmed: 11828006
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73
pubmed: 12427970
Nat Rev Cancer. 2003 Sep;3(9):666-75
pubmed: 12951585
Cancer Res. 2003 Oct 15;63(20):6838-46
pubmed: 14583481
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14151-6
pubmed: 14612578
Ann Neurol. 2004 May;55(5):654-9
pubmed: 15122705
J Immunol. 2004 Dec 15;173(12):7125-30
pubmed: 15585832
J Immunol. 2004 Dec 15;173(12):7209-16
pubmed: 15585842
J Immunol Methods. 2004 Nov;294(1-2):15-22
pubmed: 15604012
J Immunother. 2005 Jan-Feb;28(1):53-62
pubmed: 15614045
Eur Radiol. 2005 Jan;15(1):4-13
pubmed: 15616814
J Transl Med. 2005 Apr 28;3(1):17
pubmed: 15860133
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
pubmed: 15980149
Magn Reson Med. 2006 Sep;56(3):498-508
pubmed: 16897768
Cancer Res. 2007 Jan 1;67(1):354-61
pubmed: 17210718
Cancer Immunol Immunother. 2008 Feb;57(2):271-80
pubmed: 17646988
Nat Med. 2008 Jan;14(1):28-36
pubmed: 18157142
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):698-703
pubmed: 18182491
Nat Rev Cancer. 2008 Apr;8(4):299-308
pubmed: 18354418
Biotechnol Bioeng. 2008 Dec 15;101(6):1123-8
pubmed: 18563847
J Immunol. 2008 Sep 1;181(5):3099-107
pubmed: 18713980
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
Nat Rev Immunol. 2008 Dec;8(12):970-6
pubmed: 19008897
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Small. 2010 Jan;6(1):12-21
pubmed: 19844908
Nanomedicine (Lond). 2010 Jan;5(1):65-76
pubmed: 20025465
J Autoimmun. 2010 Nov;35(3):192-8
pubmed: 20655706
Magn Reson Med. 2011 Mar;65(3):756-63
pubmed: 20928869
Biomaterials. 2011 Apr;32(11):2938-52
pubmed: 21277630
J Immunol. 2011 May 15;186(10):5612-9
pubmed: 21471449
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Small. 2011 May 23;7(10):1322-37
pubmed: 21520409
Biomacromolecules. 2011 Jul 11;12(7):2440-6
pubmed: 21657799
Contrast Media Mol Imaging. 2011 Jul-Aug;6(4):314-27
pubmed: 21861291
Cancer Res. 2011 Nov 15;71(22):6997-7009
pubmed: 21948969
Immunotherapy. 2011 Oct;3(10):1223-33
pubmed: 21995573
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Cytotherapy. 2012 Jul;14(6):743-51
pubmed: 22443465
Am J Clin Oncol. 2013 Jun;36(3):224-31
pubmed: 22495453
Biomaterials. 2012 Aug;33(22):5584-92
pubmed: 22575830
Clin Cancer Res. 2013 Jan 15;19(2):336-46
pubmed: 23213058
Cancer Res. 2013 Mar 15;73(6):1892-9
pubmed: 23302230
Nat Rev Immunol. 2013 May;13(5):309-20
pubmed: 23598650
Expert Opin Drug Saf. 2013 Sep;12(5):631-45
pubmed: 23668362
Nanoscale. 2013 Dec 7;5(23):11428-37
pubmed: 23963338
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
Front Oncol. 2013 Sep 11;3:231
pubmed: 24062984
Int J Nanomedicine. 2013;8:3737-44
pubmed: 24124362
Nanotechnol Sci Appl. 2012 Sep 07;5:87-100
pubmed: 24198499
Oncoimmunology. 2013 Oct 1;2(10):e26286
pubmed: 24353912
Immunol Lett. 2014 Mar-Apr;158(1-2):167-74
pubmed: 24406504
J Nanobiotechnology. 2013;11 Suppl 1:S7
pubmed: 24564857
ACS Nano. 2014 Mar 25;8(3):2252-60
pubmed: 24564881
Nanoscale. 2015 Mar 7;7(9):3954-8
pubmed: 25652717
Nanomedicine (Lond). 2015;10(7):1063-76
pubmed: 25929565
Chin J Cancer Res. 2015 Apr;27(2):128-37
pubmed: 25937774
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
PLoS One. 2015 Jun 22;10(6):e0130249
pubmed: 26098691
Biomed Res Int. 2015;2015:143720
pubmed: 26125021
Curr Opin Immunol. 2016 Apr;39:90-5
pubmed: 26829458
Annu Rev Biomed Eng. 2016 Jul 11;18:125-58
pubmed: 26863922
Nature. 2016 Mar 31;531(7596):583-4
pubmed: 26982727
Int J Nanomedicine. 2016 Sep 14;11:4657-4668
pubmed: 27695324
Theranostics. 2016 Sep 2;6(11):2000-2014
pubmed: 27698936
F1000Res. 2016 Oct 20;5:2545
pubmed: 27803807
J Nanobiotechnology. 2019 Jan 22;17(1):14
pubmed: 30670029
ACS Nano. 2019 Feb 26;13(2):1469-1478
pubmed: 30763076
Cancer. 1994 Mar 15;73(6):1731-7
pubmed: 8156501
Cell. 1994 Jan 14;76(1):17-27
pubmed: 8287475
J Histochem Cytochem. 1998 May;46(5):627-39
pubmed: 9562571